In the last post we walked through Forteo and Tymlos, the two daily injection medications that build new bone. There is a third anabolic option, and it works through an entirely different pathway. Evenity (romosozumab) earns its own post because the differences are not minor: different mechanism, different schedule, different cap, and a boxed warning that needs careful, honest discussion. If your doctor has mentioned Evenity, here is what I want you to understand before you decide.
A Different Mechanism Entirely
Forteo and Tymlos are synthetic versions of parathyroid hormone or a related fragment. They tell your bone-building cells to get to work. Evenity does something almost no other osteoporosis medication does: it blocks a single protein called sclerostin, and that one move produces two effects at the same time.
Sclerostin is made by cells embedded throughout your bone, and its normal job is to put a brake on bone formation. When Evenity inhibits sclerostin, two things happen in parallel (NCBI StatPearls, DrugBank):
- Bone formation goes up. Your bone-building cells become more active.
- Bone resorption goes down. The cells that break down bone become less active.
This dual effect is genuinely unusual. Forteo and Tymlos build bone but also speed up turnover, meaning some resorption rises along with formation. Bisphosphonates and denosumab slow resorption but do not actively build new bone. Evenity is the only currently approved medication that pushes both directions of the equation in the favorable direction at once. The clinical result is meaningful gains in bone density, particularly at the spine, in a relatively short window.
How It Is Given
Evenity is a once-a-month treatment. Each monthly dose is two injections given back to back, usually in the back of the upper arm, the abdomen, or the thigh. The two injections are required to deliver the full dose (Evenity prescribing information).
A few practical implications. Most patients receive Evenity in their doctor's office or infusion suite rather than self-injecting at home, partly because of the two-injection logistics and partly because of the cardiovascular monitoring discussed below. The schedule is much easier to live with than a daily injection. Twelve appointments over a year rather than 365 self-injections, and many patients tell me they appreciate the predictable rhythm.
The Twelve-Month Cap
Unlike Forteo and Tymlos, where the long-standing two-year limit has softened into clinical judgment, Evenity has a 12-month treatment cap that has not changed. The bone-building effect of romosozumab plateaus after about a year, and continuing past 12 months does not provide additional benefit. The label is explicit: a course is twelve monthly doses, and that is the course.
This is not a disadvantage so much as a design feature. The 12-month window is meant to be a high-impact construction phase, immediately followed by a maintenance phase on a different medication.
The Cardiovascular Boxed Warning
This is the part that needs the most careful conversation, so I want to be straightforward about it.
Evenity carries an FDA boxed warning for myocardial infarction, stroke, and cardiovascular death (FDA label). The warning came from a large clinical trial that compared Evenity to a bisphosphonate. In that study, slightly more women on Evenity had a serious cardiovascular event during the first year compared to women on the bisphosphonate (TGA safety review). A second large trial did not show the same signal. Regulators ultimately decided the risk was real enough to warrant the strongest level of warning.
What this means in practical terms:
- Evenity should not be started in anyone who has had a heart attack or stroke in the past year.
- For patients with other cardiovascular risk factors, including established heart disease, high blood pressure, high cholesterol, diabetes, smoking history, or severe kidney impairment, the benefits and risks need an explicit conversation, not a passing mention.
- Anyone who has a heart attack or stroke during treatment should stop Evenity.
I want to put the absolute risk in context, because boxed warnings can sound more frightening than the underlying numbers. In that pivotal trial, the difference between the two groups worked out to roughly nine extra cardiovascular events per 1,000 women treated for a year. That is real and not trivial. It is also small enough that for a woman at very high fracture risk, someone who has already broken a vertebra, has a T-score below -3.0, or has not responded to other treatments, the math can still favor treatment. The point is not to dismiss the warning. The point is to weigh it honestly against your individual fracture risk and your individual cardiovascular risk, with your doctor, and to decide together.
If you have significant cardiovascular history, Evenity is probably not your medication, and Forteo or Tymlos may be the better anabolic choice.
Where It Fits in the Sequence
The same critical principle from the Forteo and Tymlos post applies here, only more so: the bone you build with Evenity is not permanent unless you follow it with an antiresorptive medication.
The clearest evidence comes from sequential therapy studies. Women who completed a year of Evenity and then transitioned to either denosumab or a bisphosphonate continued to gain bone density and had fewer fractures over the following years compared to women who never received the anabolic agent (Romosozumab Followed by Antiresorptive Treatment, PMC). A 2024 meta-analysis confirmed that this anabolic-first, antiresorptive-second sequence significantly reduces fractures of the spine, hip, and other major sites (sequential antifracturative treatment meta-analysis, PMC).
The standard sequence is twelve months of Evenity, then a transition to either a bisphosphonate (oral or IV) or denosumab. The transition should not be delayed. Without the follow-up, the gains erode quickly, and the year of treatment loses much of its value.
Who Is a Good Candidate
Pulling all of this together, Evenity tends to be considered for patients who:
- Are at very high fracture risk (recent vertebral fracture, T-score of -3.0 or lower, multiple prior fractures, or a fracture on bisphosphonate therapy)
- Need rapid bone gain, for example after a recent fragility fracture where every month matters
- Cannot tolerate or have not responded to a daily injection
- Do not have recent cardiovascular events and have manageable cardiovascular risk
- Have a clear plan for the antiresorptive medication that will follow
Evenity is a powerful, time-limited tool. Used in the right patient, with eyes open about the cardiovascular caution and a firm plan for the year-two follow-up, it can produce gains that are difficult to achieve any other way.
Questions Worth Bringing to Your Appointment
- Given my cardiovascular history, is Evenity an appropriate option for me?
- How does my fracture risk weigh against the boxed-warning risk in my specific situation?
- Will I receive the injections in your office or somewhere else?
- What antiresorptive medication will follow, and how soon after my last Evenity dose will I start it?
- How will my insurance handle prior authorization, and is there a manufacturer assistance program?
- What lab work will we monitor (calcium levels, kidney function) during treatment?
Evenity is a different kind of bone-building medication, in a different rhythm, with a different set of considerations than Forteo and Tymlos. None of the three anabolic agents is the right choice for everyone, and that is genuinely a strength of where osteoporosis treatment is now. There are real options, and matching the right one to the right patient is most of the work.
Whichever path you and your doctor choose, the rest of the story still matters: weight-bearing exercise, adequate protein, calcium and vitamin D, fall prevention, and a clear plan for what comes after the anabolic year. Medications are powerful, but they work best as one chapter in a larger plan.
If you missed the previous post on the daily anabolic injections, you can read it here.